Literature DB >> 2223919

Increased serum phospholipase A2 activity in schizophrenia: a replication study.

W F Gattaz1, C V Hübner, T J Nevalainen, T Thuren, P K Kinnunen.   

Abstract

Phospholipase A2 (PLA2) is a key enzyme in the metabolism of phospholipids. Because a disordered phospholipid metabolism has frequently been reported in schizophrenia, we investigated the PLA2 activity in serum from 14 drug-free paranoid schizophrenic patients, 20 healthy controls, and 8 nonschizophrenic psychiatric patients. Schizophrenics showed significantly higher PLA2 activity than healthy controls and nonschizophrenic patients. The increment in schizophrenics was not due to increased concentration of pancreatic secretory PLA2, as concerning pancreatic PLA2 no differences were found among the 3 proband groups. The present findings confirm the results of our previous study and suggest that increased serum PLA2 activity might reflect an increment in the intracellular enzyme activity in schizophrenia. In the brain the activation of intracellular PLA2 results in changes in neuronal activity due to alterations in receptor sensitivity and in neurotransmitter metabolism. The possibility that such PLA2-induced mechanisms are involved in the pathogenesis of schizophrenia should be investigated in further experiments.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223919

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  23 in total

1.  Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study.

Authors:  Prachi Semwal; Suman Prasad; Panchami G Varma; A M Bhagwat; S N Deshpande; B K Thelma
Journal:  J Genet       Date:  2002-08       Impact factor: 1.166

2.  Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples.

Authors:  K V Chowdari; B Brandstaetter; P Semwal; T Bhatia; S Deshpande; R Reddy; J Wood; C R Weinberg; B K Thelma; V L Nimgaonkar
Journal:  Psychiatr Genet       Date:  2001-12       Impact factor: 2.458

3.  Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia.

Authors:  J Brunner; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

4.  Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.

Authors:  Stefan Smesny; Susan Stein; Ingo Willhardt; Jürgen Lasch; Heinrich Sauer
Journal:  J Neural Transm (Vienna)       Date:  2008-06-27       Impact factor: 3.575

5.  Fatty acids and schizophrenia.

Authors:  J D Laugharne; J E Mellor; M Peet
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

6.  Chronic lithium treatment decreases brain phospholipase A2 activity.

Authors:  M C Chang; C R Jones
Journal:  Neurochem Res       Date:  1998-06       Impact factor: 3.996

7.  Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.

Authors:  M C Chang; J M Bell; A D Purdon; E G Chikhale; E Grange
Journal:  Neurochem Res       Date:  1999-03       Impact factor: 3.996

8.  Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats.

Authors:  Li-Yen Lee; Wei-Yi Ong; Akhlaq A Farooqui; Jean-Marc Burgunder
Journal:  Psychopharmacology (Berl)       Date:  2007-09-04       Impact factor: 4.530

9.  Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Authors:  S Smesny; B Milleit; U-C Hipler; C Milleit; M R Schäfer; C M Klier; M Holub; I Holzer; G E Berger; M Otto; I Nenadic; M Berk; P D McGorry; H Sauer; G P Amminger
Journal:  Mol Psychiatry       Date:  2013-03-12       Impact factor: 15.992

10.  31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms.

Authors:  H Fukuzako; K Takeuchi; K Ueyama; T Fukuzako; Y Hokazono; K Hirakawa; K Yamada; T Hashiguchi; M Takigawa; T Fujimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.